California's state prescription drug label sells one product: a long-acting insulin glargine pen, five per pack, at a suggested retail price of no more than $55. Seven months after launch, that remains the entire insulin lineup.
Vials are not available. Rapid-acting insulin is not available. And the $50 million California had set aside to build its own in-state manufacturing facility was eliminated from the budget, meaning the state is currently a brand on someone else's product rather than a manufacturer.
